Accelerate CGT development with rapid, cell-free, NGS-verified synthesis of long, complex synthetic DNA

Long, complex synthetic DNA constructs enable precise customization of genetic material enabling researchers to engineer therapeutic interventions tailored to individual patients. The intricate design of synthetic DNA sequences facilitates the delivery of therapeutic genes and regulatory elements to optimize the efficacy and safety of cell and gene therapies. The ability to rapidly manipulate and design complex DNA sequences with fewer constraints on sequence complexity is crucial for unlocking the full potential of personalized medicine, bringing targeted and effective treatments to market faster.

In March of 2023, Elegen launched ENFINIA DNA, offering researchers linear synthetic DNA fragments that were 2x longer and 20x more accurate than the fragments available on the market. ENFINIA DNA is produced from Elegen’s proprietary cell-free manufacturing process and shipped NGS-verified at lengths up to 7kb in as few as 7 days. Following a successful early access program, Elegen is now launching new sequence acceptance criteria that will enable researchers to order the same high-accuracy long DNA with industry-leading sequence complexity.

In this webinar, members of the Elegen team will discuss improvements they have made to enable the cell-free synthesis of ENFINA DNA constructs that include a diverse range of complexities commonly used in the design and development of cell and gene therapies, including ITRs, LTRs, GC-rich promoters, hairpins, long homopolymers, short and long repeat regions, and regions with high or low GC content.

• Introduction to Elegen and their cell-free DNA manufacturing products.
• Understanding of the complex DNA sequences commonly used in the development of cell and gene therapy.
• Advantages of rapid, cell-free synthesis of long, complex synthetic DNA constructs for the development of cell and gene therapy.

Marion Meunier

Applications Scientist at Elegen

Marion Meunier is an Applications Scientist at Elegen, where she oversees providing customers with early access to product innovations and new technologies. She holds a PhD in Biological Sciences from UCSD and brings previous experience at the forefront of DNA synthesis from her time at Telesis Bio.

Ben Allred

Staff Scientist at Elegen

Ben Allred is currently a Staff Scientist at ELEGEN developing DNA synthesis methods. His previous experience includes DNA chemist at Complete Genomics, a postdoc in DNA biophysics, and a PhD in synthetic chemistry.

Watch now

SPEAKERS

Marion Meunier

Applications Scientist at Elegen

Ben Allred

Staff Scientist at Elegen

You might also like

Same-section spatial multiomics: a platform for detailed analysis of the solid tumor TME

Emily Neil, Ariadna Pascual

27 June

in 50

Days

Register

Specifications don’t tell the whole story: how to choose GMP process and QC equipment

M Kay Bates, W Marin, K Whitlatch

18 June

in 41

Days

Register

Revolutionary innovations are underway to industrialize cell and gene therapies

Mark Santos

13 June

in 36

Days

Register

Quadplex dPCR as a tool to analyze genome integrity and heterogeneity in gene therapy drug products

Ryan Massopust

11 June

in 34

Days

Register

Mastering the journey from initial method transfer to successful lot release for cell & gene therapies

A Chang, H Malicki, J Cheung et al.

6 June

in 29

Days

Register